Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)

ClinicalTrials.gov ID: NCT07927491

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07927491. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 and Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM) Characterized by Epidermal Growth Factor Receptor (EGFR) Mutation or Amplification

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, first-in-human phase 1 and surgical window of opportunity study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of CM93 in subjects with recurrent glioblastoma (rGBM) characterized by Epidermal Growth Factor Receptor (EGFR) amplification/mutation who have previously received at least 1st-line high-grade glioma therapy.

Study identification

NCT ID: NCT07927491
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: NYU Langone Health; Other
Enrollment: 72 participants

Conditions and interventions

Conditions

Recurrent Glioblastoma With EGFR Mutation

Interventions

CM93 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 1, 2026 (Estimated)
Primary completion: Jun 1, 2031 (Estimated)
Completion: Dec 1, 2032 (Estimated)
Last update posted: Nov 10, 2026

2026 – 2032

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Mass General Brigham	Boston	Massachusetts	02199	—
Mayo Clinic	Rochester	Minnesota	55905	—
NYU Langone Health	New York	New York	10016	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07927491, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 10, 2026 · Synced Nov 15, 2026